help me understand telehealth, I have read the wiki twice
help me understand telehealth, I have read the wiki twice. Searched first, found three threads that contradict each other, hence the post.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
a 503B has to register and report, so there is a paper trail to ask for
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
the pharmacy and the prescriber are two separate questions
ask what the beyond-use date is based on
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Is the compound still on the shortage list where you are?
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material.
camila_sandvik is right about the concentration trap. It breaks arithmetic that has been reliable for months.
a telehealth intake that asks nothing has told you what it is
compounded is not generic, there is no equivalence claim
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
This is the distinction the whole board runs on. Everything else follows from it.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
- 1Potency and sterility testing on the finished preparation are separate from…14 comments in this branch · started by u/camila_sandvik
- 2Reminder that nothing here is medical advice and this board cannot tell you…8 comments in this branch · started by u/quiet_moderator